Software cutting-edge platforms for research
We serve innovative Biotech SME's and Academic Research Institutions, with its innovative software platform for drug discovery. We offers services based on its state-of-the-art technology platform, a broad range of integrated capabilities spanning the drug discovery process, and scientists with many years of experience in the industry. We cover a broad range of services:
- Target ID and validation
- Hit identification
- Sample management
- Chemistry
- Drug Metabolism and Pharmacokinetics, Absorption, Distribution, Metabolism, Excretion and Toxicity
- Proteomics and metabolomics
- Bio reagents
- Biomarkers
- In vivo pharmacology
- In vitro biology
Cardio-vascular and Metabolic research
We work closely with private and public scientific teams to provide our partners with innovative solutions, high quality services and scientific excellence. We provide software libraries for metabolic diseases and drug discovery in
- diabetes,
- obesity,
- pancreatic ß-cell function
and offer a complete array of preclinical solutions for compound testing and target validation using state-of-the-art approaches and experimental models.
In the area of cardiovascular diseases, we prioritize the generation of preclinical and early clinical proof-of-concept evidence to optimize drug development. We bring an innovative vision to research by combining key clinical pharmacology solutions with scientific expertise in cardiovascular diseases.
Oncology
Our dedicated solutions help biotech and academic organizations in their drug discovery research activities offering a comprehensive panel of activities from target identification to pre-clinical candidate through a highly sophisticated and integrated drug discovery platform.
IN VITRO TOOLS: Extensive libraries in molecular biology, biochemical, biophysical and cellular assay systems for oncology targets including kinases, metabolic enzymes and PPIs. Target identification approaches via phenotypic or CRISPR screens and chemical biology. Customized high-content imaging assays for phenotypic screening through to supporting lead optimization. In vitro antibody evaluation know-how strongly connected with biophysical methods (antibody biochemical characterization and efficacy evaluation). Specific assays to study the microenvironment (immune cells, fibroblasts, adipocytes, endothelial cells), targeted therapy resistance, and drug impact on cancer metabolism
IN VIVO TOOLS: Establishment of PK/PD relationships using target engagement or surrogate markers. Syngeneic, orthotopic tumour xenografts to track anti-tumour and microenvironment effects. Development of novel models, as well as humanised mouse, spontaneous metastasis, angiogenesis and alopecia models. Histology, morphometric analysis, immune- and MS-based approaches combined with in vivopharmacology to analyse disease-relevant biomarkers. ELISpot for IFNg production of splenocyte-derived activated T-cells.
©Copyright. All rights reserved.
We need your consent to load the translations
We use a third-party service to translate the website content that may collect data about your activity. Please review the details in the privacy policy and accept the service to view the translations.